Selective oestrogen receptor modulators effectively reduce breast cancer in women at moderate to high risk, so why aren’t they being discussed routinely?
Using medication to prevent breast cancer in women at moderate and high risk is a cost-effective1 and immediately implementable strategy for reducing the burden of breast cancer in Australia. There is Level 1 (strong) evidence that selective oestrogen receptor modulators (SERMs) such as tamoxifen and raloxifene reduce breast cancer risk by up to 40% in these women.2 The absolute risk reduction depends on an individual’s risk factor profile.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Bishop JF, Glass P, Pezzullo ML, et al. The health economics of chemoprevention for breast cancer in Australia. Sydney: Cancer Institute, 2008. (CI NSW Cat. No. IM-2008-01.) http://www.cancerinstitute.org.au/media/78100/im-2008-01_chemoprevention_bc.pdf (accessed Oct 2011).
- 2. Visvanathan K, Chlebowski RT, Hurley P, et al. American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 2009; 27: 3235-3258.
- 3. Keogh LA, Hopper JL, Rosenthal D, Phillips KA. Australian clinicians and chemoprevention for women at high familial risk for breast cancer. Hered Cancer Clin Pract 2009; 7: 9.
- 4. National Breast and Ovarian Cancer Centre. Advice about familial aspects of breast cancer and epithelial ovarian cancer. Sydney: NBOCC, 2010. http://canceraustralia.nbocc.org.au/view-document-details/bog-advice-about-familial-aspects-of-breast-cancer-and-epithelial-ovarian-cancer (accessed Oct 2011).
- 5. Phillips KA, Glendon G, Knight JA. Putting the risk of breast cancer in perspective. N Engl J Med 1999; 340: 141-144.
- 6. Amir E, Freedman OC, Seruga B, et al. Assessing women at high risk of breast cancer: a review of risk assessment models. J Natl Cancer Inst 2010; 102: 680-691.
- 7. Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancer — 96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007; 99: 272-282.
- 8. Powles TJ, Ashley S, Tidy A, et al. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 2007; 99: 283-290.
- 9. Veronesi U, Maisonneuve P, Rotmensz N, et al. Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst 2003; 95: 160-165.
- 10. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005; 97: 1652-1662.
- 11. Vogel VG, Costantino JP, Wickerham DL, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res (Phila) 2010; 3: 696-706.
- 12. Shen Y, Costantino JP, Qin J. Tamoxifen chemoprevention treatment and time to first diagnosis of estrogen receptor-negative breast cancer. J Natl Cancer Inst 2008; 100: 1448-1453.
- 13. Day R, Ganz PA, Costantino JP, et al. Quality of life and tamoxifen in a breast cancer prevention trial: a summary of findings from the NSABP P-1 study. National Surgical Adjuvant Breast and Bowel Project. Ann N Y Acad Sci 2001; 949: 143-150.
- 14. Drife J. Oral contraception and the risk of thromboembolism: what does it mean to clinicians and their patients? Drug Safety 2002; 25: 893-902.
- 15. Nelson HD, Fu R, Griffin JC, et al. Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer. Ann Intern Med 2009; 151: 703-715, W-226-35.
- 16. Phillips KA. Approaches to reducing cancer risk in women with a mutation in BRCA1 or BRCA2. Asia-Pac J Clin Oncol 2009; 5 Suppl 1: A48.
- 17. Phillips KA, Jenkins MA, Lindeman GJ, et al. Risk-reducing surgery, screening and chemoprevention practices of BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Clin Genet 2006; 70: 198-206.
- 18. Kerlikowske K, Grady D, Rubin SM, et al. Efficacy of screening mammography. A meta-analysis. JAMA 1995; 273: 149-154.
- 19. Goss PE, Ingle JN, Ales-Martinez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011; available online ahead of print.
- 20. Heisey R, Pimlott N, Clemons M, et al. Women’s views on chemoprevention of breast cancer: qualitative study. Can Fam Physician 2006; 52: 624-625.
- 21. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
- 22. Gazarian M, Kelly M, McPhee JR, et al. Off-label use of medicines: consensus recommendations for evaluating appropriateness. Med J Aust 2006; 185: 544-548. <MJA full text>
- 23. Antill YC, Shanahan M, Phillips KA. The integrated, multidisciplinary clinic: a new model for the ongoing management of women at high genetic risk for breast and ovarian cancer. Cancer Forum 2005; 29: 107-110.
Online responses are no longer available. Please refer to our instructions for authors page for more information.
We thank Alison Trainer for her critical review of the manuscript. Kelly-Anne Phillips is the Dr John Colebatch Clinical Research Fellow of the Cancer Council, Victoria.
No relevant disclosures.